Abstract
Caffeine, a stimulant largely consumed around the world, is a non-selective adenosine receptor antagonist, and therefore caffeine actions at synapses usually, but not always, mirror those of adenosine. Importantly, different adenosine receptors with opposing regulatory actions co-exist at synapses. Through both inhibitory and excitatory high-affinity receptors (A1R and A2R, respectively), adenosine affects NMDA receptor (NMDAR) function at the hippocampus, but surprisingly, there is a lack of knowledge on the effects of caffeine upon this ionotropic glutamatergic receptor deeply involved in both positive (plasticity) and negative (excitotoxicity) synaptic actions. We thus aimed to elucidate the effects of caffeine upon NMDAR-mediated excitatory post-synaptic currents (NMDAR-EPSCs), and its implications upon neuronal Ca2+ homeostasis. We found that caffeine (30–200 μM) facilitates NMDAR-EPSCs on pyramidal CA1 neurons from Balbc/ByJ male mice, an action mimicked, as well as occluded, by 1,3-dipropyl-cyclopentylxantine (DPCPX, 50 nM), thus likely mediated by blockade of inhibitory A1Rs. This action of caffeine cannot be attributed to a pre-synaptic facilitation of transmission because caffeine even increased paired-pulse facilitation of NMDA-EPSCs, indicative of an inhibition of neurotransmitter release. Adenosine A2ARs are involved in this likely pre-synaptic action since the effect of caffeine was mimicked by the A2AR antagonist, SCH58261 (50 nM). Furthermore, caffeine increased the frequency of Ca2+ transients in neuronal cell culture, an action mimicked by the A1R antagonist, DPCPX, and prevented by NMDAR blockade with AP5 (50 μM). Altogether, these results show for the first time an influence of caffeine on NMDA receptor activity at the hippocampus, with impact in neuronal Ca2+ homeostasis.
Keywords: Caffeine, NMDAR, Hippocampus, A1 adenosine receptor, A2A adenosine receptor
Introduction
Caffeine is a psychoactive drug widely consumed in the world and has a plethora of actions in the central nervous system (CNS) [1]. Nowadays, in addition to traditional beverages such as coffee and tea, caffeine can be found in energy drinks, soft drinks, and chocolates [2, 3]. The consumption of these products increased in recent years, including in children and adolescents [4–6], and may even exceed the recommended daily intake (2.5 mg/kg for 6–12 years old children) due to advertisements designed to attract these young consumers [7–9].
Caffeine is a methylxanthine with several mechanisms of action, such as non-selective antagonism of adenosine receptors, as the high-affinity A1 and A2A adenosine receptor (A1R and A2AR) subtypes, inhibition of cyclic nucleotide phosphodiesterases, mobilization of Ca2+ from the sarcoplasmic reticulum or inhibition of its reuptake, inhibition of monoamine oxidase and cyclooxygenase enzymes, and blockade of GABAA receptors [2, 10–15].
Adenosine A1R and A2AR are widely distributed in the CNS. The A1R is expressed in pre- and post-synaptic sites [16, 17] with its greatest expression on the cortex, cerebellum, and hippocampus [16, 18, 19]. The A2AR is mostly expressed in the basal ganglia but it is also present in the cortex and hippocampus, with pre- and post-synaptic actions being reported [20–24].
Adenosine is a homeostatic regulator of neuronal function, and therefore the blockade of its receptors by caffeine impacts on central nervous system activity. This has been explored in the context of the putative therapeutic actions of caffeine. Indeed, since A2AR can promote excitotoxicity, several studies have looked for neuroprotective effects of caffeine or related compounds in neurodegenerative diseases, including memory impairment observed in Alzheimer’s disease (AD) or aging [14, 25, 26]. In addition, several studies have identified an effect of caffeine on synaptic plasticity, learning, and memory, which is usually observed after long-term caffeine treatment, and demonstrate an improvement in hippocampus-dependent learning, short-term memory, and LTP, in animal models for AD, sleep deprivation, or aging [27–29].
The A1R antagonism is responsible for the excitatory effect of caffeine upon synaptic transmission, while A2AR antagonism mediates the inhibitory action of caffeine upon synaptic plasticity [28, 30]. N-methyl-d-aspartate receptor (NMDAR) is an ionotropic glutamate receptor involved not only in several forms of synaptic plasticity but also in excitotoxicity due to its Ca2+-permeable ion channel properties [31, 32]. Direct evidence for post-synaptic modulation of hippocampal NMDA receptors by adenosine A1R has been obtained long ago [33, 34], while A2AR has been recently reported as post-synaptic modulators of NMDA receptors at the hippocampus of young adult rats [24]. A2AR is also known to interact with other neurotransmitter receptors to control NMDA receptor activity at the hippocampus [35–40].
The impact of adenosine A1R- and A2AR-mediated NMDA receptor modulation for neuroprotection, synaptic plasticity, learning, and memory has been repeatedly highlighted and discussed [24, 35, 41–46]. Since caffeine antagonizes A1R and A2AR, and since these receptors co-exist at different levels at the tripartite synapses, frequently having opposite roles in neuronal function, it is of uttermost importance to understand how this widely consumed substance modulates a receptor that also has a dual role on synapses. Therefore, the aim of this work was to evaluate the acute effect of caffeine on NMDAR-mediated currents of pyramidal neurons of the hippocampal Cornu Ammonis 1 region (CA1), as well as to evaluate the contribution of this action of caffeine on Ca2+ signaling in hippocampal neurons.
Experimental procedures
All experimental procedures were performed according to European Community Guidelines (Directive 2010/63/EU) and the Portuguese Law (DL 113/2013) for animal care for research purposes and were approved by the “Instituto de Medicina Molecular João Lobo Antunes” Internal Committee and the Portuguese Animal Ethics Committee-Direcção Geral de Veterinária.
Whole cell patch clamp recordings
Young mice Balbc/ByJ males (PN35-48 days) were deeply anesthetized with isoflurane and euthanized by decapitation. The brain was quickly removed and hemispheres isolated for hippocampal dissection in 4 °C dissecting solution containing (in mM) sucrose 110; KCl 2.5; CaCl2 0.5; MgCl2 7; NaHCO3 25; NaH2PO4 1.25; and glucose 7, pH = 7.4, aired with 95% O2 and 5% CO2. Transversal hippocampal slices (300 μm thick) were made using a vibratome (Leica VT 1000S; Leica Microsystems, Germany) routinely in the laboratory (e.g., [24]). Slices were then incubated for 30 min at 35 °C in artificial cerebrospinal fluid (aCSF) containing (mM) NaCl 124; KCl 3; NaH2PO4 1.25; NaHCO3 26; MgSO4 1; CaCl2 2; and glucose 10, pH 7.4, gassed with 95% O2 and 5% CO2, and then allowed to further energetic recover at room temperature for at least 1 h, before starting recordings. Throughout the recording period, the aCSF was supplemented with 5 μM glycine and no Mg2+ was added.
For recordings, individual slices were fixed with a grid in a recording chamber and continuously superfused with modified aCSF (supplemented with 5 μM glycine and no Mg2+) at room temperature by a gravitational superfusion system at 2–3 mL/min. NMDAR-mediated synaptic currents were pharmacologically isolated with the addition of picrotoxin (GABAA receptor blocker—50 μM) and 6-cyano-7-nitroquinoxaline-2,3-dione disodium salt hydrate (CNQX—α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) blocker—10 μM) to the perfusion medium (modified aCSF) during all recording time. Recorded signals were allowed to stabilize for at least 10 min before the addition of any test drug. Tested drugs were added to the superfusion solution; 0 min in the time-course figures indicate the time at which the changeover of solutions was initiated. When caffeine was tested in presence of other drug, caffeine was added to superfusion solution at 0 min, while the other drug was added at least for 10 min, before caffeine addition, during the baseline period, as indicated in the time-course figures. Whenever changing solutions, around 2–3 min elapsed before the new solution reaches the recording chamber.
Patch pipettes (4–9 MΩ) were pulled from borosilicate glass capillaries (1.5-mm outer diameter, 0.86 inner diameter, Harvard Apparatus) with a PC-10 Puller (Narishige Group) and filled with an intracellular solution containing (mM) K-gluconate 125; KCl 11; CaCl2 0.1; MgCl2 2; EGTA 1; HEPES 10; MgATP 2; NaGTP 0.3; and phosphocreatine 10, pH 7.3, adjusted with KOH (1 M), 280–290 mOsm. Electrode positioning and cell selection were performed under visual guidance using a Carl Zeiss Axioskop 2FS upright microscope (Jena, Germany) equipped with a differential interference contrast-infrared (DIC-IR) CCD video camera (VX44, Till Photonics, Gräfelfing, Germany).
Recordings from CA1 pyramidal cells were performed in voltage-clamp mode (Vh = − 60 mv) with an Axopatch 200B amplifier (Axon Instruments, CA, USA). Excitatory post-synaptic currents (EPSCs) were electrically evoked every 15 s by an electric pulse delivered through a bipolar concentric electrode (Advent Research Materials) placed on the side fibers of Schaffer collaterals. For the paired-pulse facilitation (PPF) assessment, 2 pulses separated by 250 ms were delivered every 15 s. The junction potential was not compensated for and offset potentials were nulled before giga-seal formation. Small voltage steps (5 mV, 50 ms) were delivered throughout the experiment to monitor the access resistance; the holding current was also constantly monitored and when any of these parameters varied by more than 20%, the experiment was rejected. The current signal was low-pass filtered using a 3- and 10-kHz three-pole Bessel filter, digitized at 10 kHz using a Digidata 1322A board, and registered by the Clampex software version 10.2 (Molecular Devices, Sunnyvale, CA, USA). Data analysis was performed with Clampfit 10 (included in pCLAMP 10).
Primary culture of neurons
Primary purified neuron cultures were prepared according to established methodology (e.g., [47]). Briefly, Sprague-Dawley fetuses (pre-natal day 18/19) were sacrificed and their brains used to grow primary neuronal cultures. The fetuses were collected in Hank’s balanced salt solution (HBSS), their cerebral cortex together with the hippocampus was isolated, the meninges were removed, and the tissue was prepared for co-culture. The obtained tissues were mechanically fragmented and digested with 10% (v/v) trypsin-ethylenediaminetetraacetic acid (EDTA) in HBSS for 15 min at 37 °C. Trypsin action was stopped with the addition of a solution with 30% (v/v) fetal bovine serum (FBS) in HBSS, followed by 3× centrifugation at 1200 rpm (Eppendorf, 5810R, Hamburg, Germany); in each cycle, the medium was discarded and renewed with 30% (v/v) FBS in HBSS solution. After the last centrifugation, cells were resuspended in supplemented Neurobasal medium (0.5 mM l-glutamine, 25 μM glutamic acid, 2% (v/v) B-27, and 12 μg/mL gentamycin). Cells were strained through a nylon filter (70 μm), and then 200 μl of the supernatant with an average density of 5000 cells per well was plated in 9.4 × 10.7 × 6.8 (mm) 8-well glass-bottom plates (ibidi GmbH, Martinsried, Germany) previously coated with Poly-d-lysine (PDL) for at least 2 h and washed 3 times with sterile water. Until the day of the experiments, the plated cells were maintained in a humid atmosphere (5% CO2) at 37 °C with 150 μl of Neurobasal growth medium being added on the seventh day of culture (DIC).
Ca2+ imaging
Ca2+ signaling recordings from cultured neurons were done as before [48]. Ibidi plates were mounted on an inverted microscope (Axiovert 135TV, Zeiss) with a xenon lamp and 340-nm and 380-nm wavelength bandpass filters. Throughout the experiment, the cells were kept at 37 °C in a humid atmosphere. During the first 5 min of the trial, baseline Ca2+ levels were established. Test drugs were then applied directly to the medium with a pipette. At the end of the experiment, the Ca2+ ionophore, ionomycin (2 μM), was added and only the cells that clearly responded to ionomycin with a clear increase in the 340/380 nm ratio were considered for statistical analysis. Zero minutes in the time-course figures represent the time when recordings begun.
Image pairs were taken every 10 s with excitation wavelengths of 340 and 380 nm and then used to obtain respective ratio images. The excitation wavelengths were changed using a high-speed wavelength switch, Lambda DG-4 (Sutter Instrument, Novato, CA, USA), and the emission wavelength was set to 510 nm. Image data were recorded by a CCD camera (Photometrics CoolSNAP fx) and processed and analyzed by MetaFluor software (Universal Imaging, West Chester, PA, USA). The regions of interest were obtained by profiling the cells and averaging fluorescence intensity within the delimited area. Intensity values were converted to the 340/380 nm ratio and all values in each cell were normalized to the first recorded ratio.
Ca2+ imaging analysis
The frequency of Ca2+ transients was determined with MATLAB and Statistics Toolbox Release 2016a, The MathWorks, Inc. (Natick, MA, USA), with a specific roadmap. In the first 5 min of the experiment, a baseline was obtained. Mean and standard error of the mean (S.E.M) of all data recorded by each cell was obtained. Transient validation was performed as described by [49] with some modifications. Cells that had spontaneous Ca2+ transients during the first 5 min of the experiment were discarded from the statistical analysis. For a Ca2+ transient to be considered valid, the following criteria had to be met: only if the fura-2 excitation wavelength 340-nm and 380-nm (F340/380) ratio transient was greater than the mean of baseline values plus 15 times the S.E.M. of the baseline values that Ca2+ transient would be considered. In addition, the normalized ratio must be above this margin for more than 10 s and less than 700 s. For each region of interest, the peak of each transient, as well as the occurrence of transients, was recorded.
Statistical analysis
The statistical analysis was obtained utilizing the software GraphPad Prism 6.01 (GraphPad Software, Inc.). The paired data with two data groups were analyzed using either Student’s t test or Wilcoxon matched-pairs signed-rank test. Data with more than two groups analyzed were analyzed by a univariate or multivariate ANOVA followed by the Bonferroni post hoc test. The data are expressed as mean ± S.E.M. For all tests, p < 0.05 was considered to be statistically significant.
Results
Caffeine enhances NMDAR-mediated synaptic currents, an action mimicked by a selective A1R antagonist
The effect of caffeine on synaptic currents mediated by NMDAR in CA1 hippocampal pyramidal neurons of adolescent mice is summarized in Fig.1. At a concentration (200 μM) that fully blocks adenosine receptors [11, 12], it caused a fast and significant increase (47 ± 12%, n = 16 cells from 16 slices from 8 mice, p < 0.005) in the amplitude of NMDAR-mediated currents (Fig. 1a,c). At this concentration, caffeine also affects other signaling mechanisms besides blockade of adenosine receptors, as inhibition of phosphodiesterases and Ca2+ release from intracellular stores, among others [11, 12], which could be responsible for an excitatory action upon synaptic transmission. To find out whether the facilitation of NMDAR currents by caffeine could be attributed to antagonism of adenosine receptors, we designed three independent experiments aiming (1) to test the action of caffeine at a concentration (30 μM) that, though submaximal in what respects adenosine receptor blockade, is known to cause minimal effects on phosphodiesterases or other signaling mechanisms [11, 12]; (2) to compare the action of caffeine with the action of a selective antagonist of the inhibitory A1R receptor; (3) to test whether the facilitatory action of caffeine could be occluded by previous blockade of adenosine A1R.
Caffeine (30 μM) also enhanced the peak amplitude of NMDAR-mediated EPSCs (% increase: 47 ± 16%, n = 9 cells from 9 slices from 5 mice, p < 0.03%, Fig. 1a,c), the magnitude of the effect being similar to that obtained with 200 μM (Fig. 1a,c). The selective A1R antagonist, DPCPX (50 nM), also increased the amplitude of the NMDAR-mediated EPSCs (% increase: 54 ± 14%, n = 6 cells from 6 slices from 4 mice, p < 0.03% Fig. 1a, c), though with a slightly slower time course than caffeine (Fig. 1a). Importantly, in slices that had been previously incubated with DPCPX for 15 min before testing the effect of caffeine, this xanthine was unable to further facilitate NMDAR-mediated EPSCs (% change of currents caused by caffeine in the presence of DPCPX: 1.8 ± 8.4%, n = 9 cells from 9 slices from 5 mice Fig. 1b,c).
Altogether, these results indicate that the main mechanism operated by caffeine to increase NMDAR-mediated synaptic currents at the hippocampus is the blockade of A1R.
The facilitatory action of caffeine upon NMDAR-mediated EPSCs cannot be attributed to a pre-synaptic facilitatory action upon glutamate release
Adenosine A1R are known to inhibit the release of neurotransmitters, including the release of glutamate by hippocampal glutamatergic nerve terminals [44, 50, 51]. Therefore, we first hypothesized that caffeine was enhancing NMDAR-mediated EPSCs through a pre-synaptic facilitatory action that would lead to increased availability of glutamate to activate NMDARs. To test this hypothesis, we evaluated the influence of caffeine upon paired-pulse facilitation (PPF, measured as the ratio between 2nd and 1st NMDAR-mediated EPSC amplitude, interstimulus interval of 250 ms). PPF results from the transient accumulation of calcium inside the nerve terminal due to the two consecutive stimuli and reflects the synaptic release probability, so that the lower the release probability, the higher the PPF [52, 53]. Therefore, drugs that facilitate neurotransmitter release are expected to cause a decrease in PPF. Surprisingly, caffeine increased PPF of NMDAR-mediated EPSCs (Fig. 2a: Basal: 1.34 ± 0.08, n = 11 cells from 11 slices from 6 mice; Caffeine: 1.70 ± 0.19, n = 11 cells from 11 slices from 6 mice p < 0.03), precluding the possibility that its facilitatory action on NMDA-mediated EPSCs would result from a facilitation of glutamate release.
Blockade of pre-synaptic A2AR is likely involved in a pre-synaptic inhibitory action of caffeine upon transmission
The next series of experiments were designed to understand the nature of the increase in PPF observed in the presence of caffeine. To control for the possibility of a time-dependent run-down of neurotransmitter release leading to a time-dependent increase in PPF, we performed control recordings in the absence of caffeine, keeping the recording time similar to that in the caffeine protocols. Under these control conditions, PPF was not increased (Fig. 2b: Basal: 1.22 ± 0.06, n = 6 cells from 6 slices from 4 mice; % change: 1.19 ± 0.03, n = 6 cells from 6 slices from 4 mice, p > 0.05).
We then compared the action of caffeine upon PPF with that of selective A1R or A2AR antagonists. The enhancement in PPF caused by caffeine could not be attributed to adenosine A1R blockade because it was not mimicked by DPCPX (Fig. 2c: Basal: 1.31 ± 0.10, n = 7 cells from 7 slices from 5 mice; DPCPX: 1.20 ± 0.04, n = 7 cells from 7 slices from 5 mice). It was, however, mimicked by SCH 58261 at a concentration (50 nM), selective antagonist for adenosine A2AR [54–56] (Fig. 2d, Basal: 1.42 ± 0.08, n = 6 cells from 6 slices from 4 mice; SCH 58261: 1.90 ± 0.30, n = 6 cells from 6 slices from 4 mice, p < 0.03).
Altogether, this data suggests that caffeine modulates NMDAR-mediated synaptic currents in two ways: by blocking A1R, it likely causes a post-synaptic enhancement of transmission, and by blocking A2AR, it likely decreases availability of glutamate to activate NMDARs.
Caffeine enhances neuronal intracellular Ca2+ through A1R blockade
Considering the relevance of intracellular Ca2+ levels for both neurotransmitter release and for the NMDAR-mediated signaling cascade, and considering that caffeine can affect intracellular Ca2+ levels, either through adenosine receptor–dependent and adenosine receptor–independent ways [2, 12, 13], we tested the influence of caffeine on intracellular neuronal Ca2+ levels and assessed the role of A1R and A2AR selective antagonists in that action. We evaluated Ca2+ signaling by the fluorescence intensity response of Fura2 after consecutive stimulation at 340 nm and 380 nm, and quantified in individual cells the ratio between the two responses (F340/380, Fig. 3c). In a first set of experiments, we tested each drug individually as well as the time-dependent change in the signaling (protocol as in Fig. 3a). Recordings for 35 min after mimicking a drug change (aCSF for aCSF) did not lead to appreciable modifications in the F340/380 ratio (Fig. 3d-e). Caffeine (200 μM) caused an increase (p < 0.03) in the basal F340/380 ratio (Fig. 3d–g) as well as increased the frequency of transient Ca2+ signaling events (Fig. 3f, j; FrequencyBasal: 0.25 ± 0.06 Ca2+ Events/5 min, n = 42ǀ4; FrequencyCaffeine: 0.78 ± 0.10 Ca2+ Events/5 min, n = 180ǀ11 p < 0.04). DPCPX (50 nM) mimicked the effect of caffeine upon basal Ca2+ levels (Fig. 3d, h) as well as upon the frequency of spontaneous events (Fig. 3 h, j; FrequencyDPCPX: 0.89 ± 0.19 Ca2+ Events/5 min, n = 57ǀ3, p < 0.04 vs basal). In contrast, SCH 58261 (50 nM) did not appreciably affect either basal Ca2+ levels (Fig. 3d, k) and even decreased by near one-half the frequency of spontaneous events (Fig. 3m, FrequencySCH58261: 0.11 ± 0.04 Ca2+ Events/5 min, n = 54ǀ3 vs FrequencyBasal: 0.25 ± 0.06 Ca2+ Events/5 min, n = 42ǀ4), though this effect did not prove statistically significant.
Next, we evaluated whether a pre-incubation with each of the selective adenosine receptor antagonists could blunt the action of caffeine. Upon addition of DPCPX (50 nM), an initial rise in the F340/380 ratio was detected (Fig. 3i) in agreement with the data obtained in the previous experiments (Fig. 3h). After 15 min in DPCPX, we added caffeine (200 μM), keeping the presence of DPCPX. Under such conditions, the F340/380 ratio started to decrease back to initial levels (Fig. 3i), suggesting that caffeine has an inhibitory action upon intracellular Ca2+ levels, which can be detected when A1R is blocked. The frequency of signal transients was also decreased by caffeine (200 μM) in the presence of DPCPX (p < 0.04 when comparing DPCPX alone with DPCPX with caffeine), towards values (FrequencyDPCPX + Caffeine: 0.16 ± 0.04 Ca2+ Events/5 min, n = 28ǀ3) even slightly lower than those detected before addition of any drug (Fig. 3j).
Considering that inhibitory action of caffeine in the presence of DPCPX had similarities with the effect of the selective A2AR antagonist, SCH 58261 (50 nM), when applied alone, we hypothesized that it could result from blockade of A2AR. If so, the effect should be blunted by the presence of SCH 58261. It was indeed the case, as can be concluded from the data in Fig. 3m. When caffeine (200 μM) was applied in the presence of SCH 58261, it not only did not inhibit the frequency of Ca2+ signals, but even tended to increase the frequency towards a value (FrequencySCH58261 + Caffeine: 0.45 ± 0.22 Ca2+ Events/5 min, n = 28ǀ3) intermediate from that observed with caffeine alone and in absence of any drugs (Fig.3l, m).
We then tested the effect of a lower concentration of caffeine (30 μM) to mitigate its adenosine receptor–independent action upon mobilization of intracellular Ca2+ stores. We confirmed that even at this lower and submaximal concentration, caffeine could promote an increase in the frequency of Ca2+ transients (Fig. 4a–c: FrequencyBasal: 0.29 ± 0.07 Ca2+ Events/5 min, n = 43ǀ4; FrequencyCaffeine 30 μM: 0.61 ± 0.08 Ca2+ Events/5 min, n = 48ǀ2, p < 0.009), though being virtually devoid of effect in basal Ca2+ levels.
Altogether, these results suggest that caffeine can act at least in two opposite ways to control intracellular Ca2+ levels in neurons: (1) through blockade of A1R leading to increases in basal Ca2+ levels as well as to increases in Ca2+ transients; (2) through blockade of A2AR leading to decreases in intracellular Ca2+, an action only evident when A1R is blocked, indicating that the predominant action of caffeine is a result of A1R blockade.
NMDAR is involved in the facilitatory action of caffeine upon intracellular Ca2+ levels
It is well known that NMDAR is permeable to Ca2+ [57]. We therefore assessed whether the A1R-mediated facilitatory action of caffeine upon NMDAR could be related to the facilitatory action of this xanthine upon intracellular Ca2+ levels. To test this possibility, we evaluated the effect of caffeine upon Ca2+ signaling in neurons in presence of a NMDAR blocker, DL-2-amino-5-phosphonopentanoic acid (AP5). When applied alone, AP5 (50 μM) was virtually devoid of effect upon basal F340/380 ratio (Fig. 5b) as well as upon the frequency of the signal transients (Fig. 5d, FrequencyBasal: 0.29 ± 0.07 Ca2+Events/5 min, n = 43ǀ4; FrequencyAP5: 0.18 ± 0.04 Ca2+Events/5 min, n = 79ǀ4). Importantly, caffeine applied in the presence of AP5 could no longer increase either the basal Ca2+ levels (Fig. 5a–d) or the frequency of the transients (Fig. 5d, FrequencyAP5 + Caffeine: 0.23 ± 0.06 Ca2+Events/5 min, n = 40ǀ4). As expected, the effect of caffeine alone was significantly different (p < 0.007) from that of caffeine in the presence of AP5 (Fig. 5d). Altogether, these data show that Ca2+ entry through NMDAR contributes to the facilitatory action of caffeine upon intracellular neuronal Ca2+ signaling.
Discussion
We herein describe for the first time that acute caffeine in micromolar concentrations facilitates NMDAR-mediated synaptic currents and Ca2+ signaling on hippocampal neurons and that this effect results from A1R blockade. The facilitation of synaptic currents could not be attributed to an increase in the pre-synaptic release of glutamate. Conversely, caffeine seems to cause a decrease in glutamate release, an action mimicked by an A2AR antagonist suggesting that it may result from A2AR blockade. The net effect of caffeine on synaptic NMDAR-mediated currents is, however, a facilitatory one, indicating that under the conditions used, the A1R-mediated actions prevail over the A2AR-mediated ones, which is not surprising on the light of the relative distribution of the two high-affinity receptors at the hippocampus [17, 18]. Concerning the effect of caffeine on Ca2+ transients in neurons, we also observed a facilitation mediated by A1R blockade. The caffeine-induced enhancement of Ca2+ transients clearly involved activation of NMDAR, since it was fully prevented in the presence of a NMDAR antagonist. This highlights an inhibitory action of A1R upon Ca2+ entry through NMDAR in hippocampal neurons. Interestingly, when the A1R was blocked, caffeine slightly decreased Ca2+ signals, an effect mimicked by an A2AR antagonist. Again, the facilitation by caffeine prevails upon the inhibitory action when both high-affinity adenosine receptors were available to be blocked.
On the light of the known actions of adenosine receptors upon hippocampal synaptic transmission, the relative distribution of A1R and A2AR in hippocampal neurons, their predominance in pre-synaptic vs post-synaptic sites at hippocampal synapses [23, 58], as well on the similar affinity of caffeine for A1R and A2AR [12, 59], one would expect that most of the actions of caffeine upon glutamatergic transmission would be to canceal the pre-synaptic inhibitory action of A1R upon glutamate release. This has been the canonic interpretation for the facilitatory actions of caffeine upon hippocampal synaptic transmission [28, 56, 60], long-term potentiation [28], and induction of a non-NMDA form of synaptic plasticity [61].
Due to the relevance of NMDARs not only for synaptic platicity, cognition, memory, learning [31, 32], synapse formation, remodeling, elimination [62], neuronal migration [63], proliferation, and differentiation [64], but also for excitotoxicity [65], we focused on the possibility that caffeine could modulate the NMDAR-mediated component of glutamatergic transmission. Our data showing that caffeine ehances the NMDAR-mediated component of synaptic currents, through a mechanism that could not be related to pre-synaptic facilitation of neurotransmitter release, suggests that endogenous adenosine is tonically inhibiting NMDARs. Since this action was mimicked by DPCPX and occluded by prior application of DPCPX, the adenosine receptor involved in this tonic modulation might belong to the A1R subtype. This conclusion agrees with previous reports that post-synaptic very high-affinity adenosine A1Rs inhibit NMDA currents in dissociated hipocampal neurons [33] and highlights a role for endogenous adenosine as modulator of NMDAR function. Importantly also, we could show that it impacts in NMDAR-mediated Ca2+ oscillations in neurons. Glutamatergic synaptic maturation is highly dependent of synaptic NMDAR activation and Ca2+ oscillations at critical time points during development [66]. Thus, proper adjustment of endogenous modulation of NMDARs might be required for appropriate synaptic maturation. Caffeine exposure during gestation has been shown to affect maturation of GABAergic neurons, an action likely mediated by both A1R [67] and A2AR [68]. The present study showing that caffeine modulates synaptic responses and Ca2+ oscillations mediated by NMDARs points towards the possibility that exposure to caffeine during critical developmental periods may also affect fine tuning of glutamatergic circuits, a possibility clearly deserving future research.
The adenosine A1R–mediated protection against excitotoxicity has been mostly associated to its ability to inhibit glutamate release, whereas A2AR activation leads to excitotoxicity exacerbation [20, 44, 45] and so, neuroprotective actions of caffeine are usually a consequence of A2AR blockade. Since there is plenty of evidence on the neuroprotective actions of caffeine to delay neurodegenerative disease progression, caffeine is frequently referred as having predominant A2AR antagonistic properties. This might be so in brain areas, as the basal ganglia, where A2AR predominate, or in situations where A2AR activity gains particular relevance, as in neurodegeneration or aging, where there is an upregulation of A2AR [69]. But we now used young animals and as we show, at this age, A1R antagonism by caffeine prevails over A2AR antagonism to influence NMDAR at the hippocampus.
Evidence that tonic activation by A1R can protect neurons by decreasing NMDAR overactivation under hypoxic conditions has already been published and has been interpreted as a consequence of inhibition of neurotransmitter release [41]. The present work adds a further piece to the puzzling role of neuroprotection by adenosine by showing for the first time results compatible with the conclusion that tonic A1R activation by endogenous adenosine inhibits NMDAR-mediated responses in hippocampal neurons. As we also show, this inhibition impacts on Ca2+ homeosthasis, therefore, has a putative protective influence upon excitotoxicity, independently of the A1R-mediated ability to inhibit glutamate release.
Somehow surprising was the influence of the selective A2AR antagonist upon paired pulse facilitation of NMDAR-mediated EPSCs, an action mimicked by caffeine and compatible with a tonic facilitatory action of A2AR upon glutamate release. The selective A1R antagonist was devoid of effect upon PPF. This could result from the absence of pre-synaptic A1R activation on glutamatergic nerve terminals, which is highly unlikely, considering the well-known influence of A1R to pre-synaptically inhibit glutamate release at the hippocampus [50, 51, 70]. Indeed, while mostly assessing AMPA receptor–mediated synaptic transmission through field excitatory synaptic potential recordings, it has been observed that DPCPX [71, 72], as well as caffeine due to pre-synaptic A1R blockade [30], inhibit PPF. Alternatively, our data may indicate that the levels of endogenous adenosine in our experimental conditions are not enough to activate pre-synaptic inhibitory A1R, though being enough to activate the A1R inhibitory post-synaptic receptors that reduce NMDAR function. This possibility agrees with reports that effective concentrations of adenosine are at least one order of magnitude lower to inhibit NMDAR-mediated currents [33] than to inhibit synaptic fast excitatory synaptic transmission at the hippocampus [50, 51]. If so, one has to assume either that (1) pre-synaptic inhibitory A1R receptors have lower affinity for adenosine and/or lower efficacy to control release than pre-synaptic A2AR, or that (2) a facilitation of glutamate release due to pre-synaptic A1R blockade does not affect NMDAR-mediated responses, whereas an inhibition of glutamate release due to blockade of A2AR-mediated facilitation does. Though we cannot preclude the first possibility (affinity/efficacy differences), the second one seems likely. Thus, to activate synaptic NMDAR, there is a need of strong pre-synaptic stimulation and therefore the consequences of a further facilitation of glutamate release may be more difficult to detect than the consequences of inhibition of glutamate release. NMDAR activation may lead to further activation of NMDAR-mediated responses [73] and this could hamper the increase in EPSC caused by the second stimulus when the release is facilitated by A1R blockade. This ceiling effect is likely mitigated when release probability is lowered due to blockade of A2AR-mediated facilitation. We can also argue that paired-pulse facilitation of NMDAR-mediated currents encompasses a post-synaptic component besides a pre-synaptic one [74], and therefore the alterations of PPF caused by the A2AR antagonist and caffeine should not be interpreted only on the basis of a decrease of neurotransmitter release due to blockade of pre-synaptic A2ARs. Indeed, A2AR activation can post-synaptically facilitate NMDAR-mediated currents at the hippocampus [24] and can trigger a NMDAR-dependent form of LTP in hippocampal areas where plasticity is mostly non-NMDAR dependent [35]. A2AR are also known to facilitate synaptic plasticity phenomena both ex vivo [30] and in vivo [75]. How these A2AR-mediated actions would affect a putative post-synaptic component of the NMDA PPF is difficult to predict.
A biphasic effect of caffeine to control the release of acetylcholine has been reported [76] and tentatively interpreted as resulting from antagonism of A1 and A2 receptors known to control acetylcholine release in the cortex [77]. However, different concentrations of caffeine were required to observe the facilitatory and the inhibitory effect. We herein show that caffeine can exert this dual role at the same concentration, allowing the suggestion that the relative influence of caffeine likely depends on the relative contribution of the high-affinity adenosine receptors (A1R and A2AR) to control a specific brain function. Importantly, we report a dual role of caffeine as modulator of the activity of a receptor, the NMDA receptor, that by itself has dual functions in the brain.
In conclusion, our data suggest that acute caffeine exposure of hippocampal neurons of adolescent mice has dual and opposing effects on the NMDA component of glutamatergic synaptic transmission. The predominant action is exerted at the post-synaptic level to enhance NMDAR activity via blockade of inhibitory A1R, with a consequent increase of Ca2+ levels. By blocking facilitatory A2AR likely located pre-synaptically, caffeine leads to a decrease in glutamate release probability, a mechanism that may at least in part counteract the excitatory action upon NMDAR-mediated transmission (Fig. 7). These results, showing that relatively low concentrations of caffeine acting upon adenosine receptors can influence NMDAR activity and perturb Ca2+ oscillations at the hippocampus, highlight the need to further investigate how early exposure to caffeine during gestational periods or during adolescence affects neuronal differentiation and synaptic maturation, known to be highly dependent of properly adjusted Ca2+ homeostasis.
Acknowledgments
The authors in Portugal are members of an EU twinning action (Project grant 952455). While revising this work, the authors want to make a special tribute to Geoffrey Burnstock for his great contributions to science, for defending and enlarging the knowledge of the purinergic field to the very end of his life, for his friendship and trust even in very difficult circumstances, which will never be forgotten. Thanks Geoff. Your legacy will last forever. We will miss your loud voice and laugh.
Code availability
Not applicable
Abbreviations
- A1R
Adenosine A1 receptor
- A2AR
Adenosine A2A receptor
- aCSF
Artificial cerebrospinal fluid
- AD
Alzheimer’s disease
- AMPAR
α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor
- AP5
DL-2-Amino-5-phosphonopentanoic acid
- ARs
Adenosine receptors
- CA1
Cornu Ammonis 1
- Ca2+
Calcium ion
- CNQX
6-Cyano-7-nitroquinoxaline-2,3-dione disodium salt hydrate
- CNS
Central nervous system
- DIC
Day in culture
- DIC-IR
Differential interference contrast-infrared
- DPCPX
8-Cyclopentyl-1,3-dipropylxanthine
- EDTA
Ethylenediaminetetraacetic acid
- EPSCs
Excitatory post-synaptic currents
- F340/380
Ratio from excitation wavelength 340 nm and 380 nm
- FBS
Fetal bovine serum
- fEPSP
Field excitatory post-synaptic potential
- GABA
Gamma-aminobutyric acid
- HBSS
Hank’s balanced salt solution
- LTD
Long-term depression
- LTP
Long-term potentiation
- mGluR
Metabotropic glutamate receptors
- NMDA
N-Methyl-d-aspartate
- NMDAR
N-Methyl-d-aspartate receptor
- NMDAR-EPSCs
N-Methyl-d-aspartate receptor excitatory post-synaptic potential
- PDL
Poly-d-lysine
- PPF
Paired-pulse facilitation
- S.E.M.
Standard error of the mean
Funding
Robertta Silva Martins was in receipt of a fellowship from Fundação de Amparo à Pesquisa do Estado do Rio de Jan eiro–FAPERJ, Brasil, Bolsa de Doutorado Sanduíche Europa/Oriente (grant number E-26/201.599/2018). The work was supported by Fundação para a Ciência e Tecnologia, Portugal (project grant PTDC/MED-FAR/30933/2017).
Data availability
Not applicable
Compliance with ethical standards
Conflicts of interest
The authors declare that they have no conflict of interest.
Ethics approval
All experimental procedures were performed according to European Community Guidelines (Directive 2010/63/EU) and the Portuguese Law (DL 113/2013) for animal care for research purposes and were approved by the “Instituto de Medicina Molecular” Internal Committee and the Portuguese Animal Ethics Committee - Direcção Geral de Veterinária.
Consent to participate
Not applicable
Consent for publication
Not applicable
Footnotes
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.Meeusen R, Roelands B, Spriet LL. Caffeine, exercise and the brain. Nestle Nutr Inst work Ser. 2013;76:1–12. doi: 10.1159/000350223. [DOI] [PubMed] [Google Scholar]
- 2.Cappelletti S, Piacentino D, Sani G, Aromatario M (2015) Caffeine: cognitive and physical performance enhancer or psychoactive drug? Curr Neuropharmacol 13:71–88. /10.2174/1570159X13666141210215655 [DOI] [PMC free article] [PubMed]
- 3.Hackett PH. Caffeine at high altitude: java at base cAMP. High alt med biol. 2010;11:13–17. doi: 10.1089/ham.2009.1077. [DOI] [PubMed] [Google Scholar]
- 4.Mitchell DC, Hockenberry J, Teplansky R, Hartman TJ. Assessing dietary exposure to caffeine from beverages in the U.S. population using brand-specific versus category-specific caffeine values. Food Chem Toxicol. 2015;80:247–252. doi: 10.1016/j.fct.2015.03.024. [DOI] [PubMed] [Google Scholar]
- 5.Poole RL, Braak D, Gould TJ. Concentration- and age-dependent effects of chronic caffeine on contextual fear conditioning in C57BL/6J mice. Behav brain res. 2016;298:69–77. doi: 10.1016/j.bbr.2015.03.045. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Wikoff D, Welsh BT, Henderson R, et al. Systematic review of the potential adverse effects of caffeine consumption in healthy adults, pregnant women, adolescents, and children. Food Chem Toxicol. 2017;109:585–648. doi: 10.1016/j.fct.2017.04.002. [DOI] [PubMed] [Google Scholar]
- 7.Ludden AB, O’Brien EM, Pasch KE. Beliefs, behaviors, and contexts of adolescent caffeine use: a focus group study. Subst use misuse. 2017;52:1207–1218. doi: 10.1080/10826084.2017.1302957. [DOI] [PubMed] [Google Scholar]
- 8.Nehlig A. Effects of coffee/caffeine on brain health and disease: what should I tell my patients? Pr Neurol. 2016;16:89–95. doi: 10.1136/practneurol-2015-001162. [DOI] [PubMed] [Google Scholar]
- 9.Verster JC. Caffeine consumption in children, adolescents and adults. Curr Drug Abus Rev. 2014;7:133–134. doi: 10.2174/1874473708666150113165705. [DOI] [PubMed] [Google Scholar]
- 10.Williams M, Jarvis MF. Adenosine antagonists as potential therapeutic agents. Pharmacol Biochem Behav. 1988;29:433–441. doi: 10.1016/0091-3057(88)90182-7. [DOI] [PubMed] [Google Scholar]
- 11.Daly JW, Fredholm BB. Caffeine--an atypical drug of dependence. Drug alcohol depend. 1998;51:199–206. doi: 10.1016/s0376-8716(98)00077-5. [DOI] [PubMed] [Google Scholar]
- 12.Fredholm BB, Battig K, Holmen J, et al. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev. 1999;51:83–133. [PubMed] [Google Scholar]
- 13.Ribeiro JA, Sebastiao AM. Caffeine and adenosine. J Alzheimers Dis. 2010;20(Suppl 1):S3–S15. doi: 10.3233/JAD-2010-1379. [DOI] [PubMed] [Google Scholar]
- 14.Fredholm BB, Yang J, Wang Y. Low, but not high, dose caffeine is a readily available probe for adenosine actions. Mol asp med. 2017;55:20–25. doi: 10.1016/j.mam.2016.11.011. [DOI] [PubMed] [Google Scholar]
- 15.Dunwiddie TV, Hoffer BJ, Fredholm BB. Alkylxanthines elevate hippocampal excitability - evidence for a role of endogenous adenosine. Naunyn Schmiedebergs arch Pharmacol. 1981;316:326–330. doi: 10.1007/BF00501365. [DOI] [PubMed] [Google Scholar]
- 16.Sheth S, Brito R, Mukherjea D, et al. Adenosine receptors: expression, function and regulation. Int J Mol Sci. 2014;15:2024–2052. doi: 10.3390/ijms15022024. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Sebastião AM, Ribeiro JA. Adenosine receptors and the central nervous system. Handb Exp Pharmacol. 2009;193:471–534. doi: 10.1007/978-3-540-89615-9_16. [DOI] [PubMed] [Google Scholar]
- 18.Ribeiro JA, Sebastiao AM, de Mendonca A. Adenosine receptors in the nervous system: pathophysiological implications. Prog Neurobiol. 2002;68:377–392. doi: 10.1016/S0301-0082(02)00155-7. [DOI] [PubMed] [Google Scholar]
- 19.Fredholm BB, IJ AP, Jacobson KA, et al. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev. 2001;53:527–552. [PMC free article] [PubMed] [Google Scholar]
- 20.Sebastiao AM, Ribeiro JA. Adenosine A2 receptor-mediated excitatory actions on the nervous system. Prog Neurobiol. 1996;48:167–189. doi: 10.1016/0301-0082(95)00035-6. [DOI] [PubMed] [Google Scholar]
- 21.Li XX, Nomura T, Aihara H, Nishizaki T. Adenosine enhances glial glutamate efflux via A2a adenosine receptors. Life Sci. 2001;68:1343–1350. doi: 10.1016/S0024-3205(00)01036-5. [DOI] [PubMed] [Google Scholar]
- 22.Rodrigues RJ, Alfaro TM, Rebola N, et al. Co-localization and functional interaction between adenosine a(2A) and metabotropic group 5 receptors in glutamatergic nerve terminals of the rat striatum. J Neurochem. 2005;92:433–441. doi: 10.1111/j.1471-4159.2004.02887.x. [DOI] [PubMed] [Google Scholar]
- 23.Rebola N, Canas PM, Oliveira CR, Cunha RA (2005) Different synaptic and subsynaptic localization of adenosine A2A receptors in the hippocampus and striatum of the rat. Neuroscience 132:893–903. /10.1016/j.neuroscience.2005.01.014 [DOI] [PubMed]
- 24.Mouro FM, Rombo DM, Dias RB, et al (2018) Adenosine A2A receptors facilitate synaptic NMDA currents in CA1 pyramidal neurons. Br J Pharmacol 175:4386–4397. /10.1111/bph.14497 [DOI] [PMC free article] [PubMed]
- 25.Arendash GW, Cao C (2010) Caffeine and coffee as therapeutics against Alzheimer’s disease. J Alzheimers dis 20 Suppl 1:S117-26. /10.3233/JAD-2010-091249 [DOI] [PubMed]
- 26.de Mendonca A, Cunha RA (2010) Therapeutic opportunities for caffeine in Alzheimer’s disease and other neurodegenerative disorders. J Alzheimers dis 20 Suppl 1:S1-2. /10.3233/JAD-2010-01420 [DOI] [PubMed]
- 27.Alhaider IA, Aleisa AM, Tran TT, Alzoubi KH, Alkadhi KA. Chronic caffeine treatment prevents sleep deprivation-induced impairment of cognitive function and synaptic plasticity. Sleep. 2010;33:437–444. doi: 10.1093/sleep/33.4.437. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Costenla AR, Cunha RA, de Mendonca A. Caffeine, adenosine receptors, and synaptic plasticity. J Alzheimers dis. 2010;20(Suppl 1):S25–S34. doi: 10.3233/JAD-2010-091384. [DOI] [PubMed] [Google Scholar]
- 29.Faivre E, Coelho JE, Zornbach K, et al (2018) Beneficial effect of a selective adenosine A2A receptor antagonist in the APPswe/PS1dE9 mouse model of Alzheimer’s disease. Front Mol Neurosci 11:235. /10.3389/fnmol.2018.00235 [DOI] [PMC free article] [PubMed]
- 30.Lopes JP, Pliassova A, Cunha RA. The physiological effects of caffeine on synaptic transmission and plasticity in the mouse hippocampus selectively depend on adenosine A1 and A2A receptors. Biochem Pharmacol. 2019;166:313–321. doi: 10.1016/j.bcp.2019.06.008. [DOI] [PubMed] [Google Scholar]
- 31.Dore K, Stein IS, Brock JA, et al. Unconventional NMDA receptor signaling. J Neurosci. 2017;37:10800–10807. doi: 10.1523/JNEUROSCI.1825-17.2017. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Vyklicky V, Korinek M, Smejkalova T, et al. Structure, function, and pharmacology of NMDA receptor channels. Physiol Res. 2014;63(Suppl 1):S191–S203. doi: 10.33549/physiolres.932678. [DOI] [PubMed] [Google Scholar]
- 33.de Mendonca A, Sebastiao AM, Ribeiro JA. Inhibition of NMDA receptor-mediated currents in isolated rat hippocampal neurones by adenosine A1 receptor activation. Neuroreport. 1995;6:1097–1100. doi: 10.1097/00001756-199505300-00006. [DOI] [PubMed] [Google Scholar]
- 34.Deng Q, Terunuma M, Fellin T, et al (2011) Astrocytic activation of A1 receptors regulates the surface expression of NMDA receptors through a Src kinase dependent pathway. Glia 59:1084–1093. /10.1002/glia.21181 [DOI] [PMC free article] [PubMed]
- 35.Rebola N, Lujan R, Cunha RA, Mulle C (2008) Adenosine A2A receptors are essential for long-term potentiation of NMDA-EPSCs at hippocampal mossy fiber synapses. Neuron 57:121–134. /10.1016/j.neuron.2007.11.023 [DOI] [PubMed]
- 36.Sarantis K, Tsiamaki E, Kouvaros S, et al (2015) Adenosine a(2) a receptors permit mGluR5-evoked tyrosine phosphorylation of NR2B (Tyr1472) in rat hippocampus: a possible key mechanism in NMDA receptor modulation. J Neurochem 135:714–726. /10.1111/jnc.13291 [DOI] [PubMed]
- 37.Kouvaros S, Papatheodoropoulos C (2016) Major dorsoventral differences in the modulation of the local CA1 hippocampal network by NMDA, mGlu5, adenosine A2A and cannabinoid CB1 receptors. Neuroscience 317:47–64. /10.1016/j.neuroscience.2015.12.059 [DOI] [PubMed]
- 38.Tebano MT, Martire A, Rebola N, et al (2005) Adenosine A2A receptors and metabotropic glutamate 5 receptors are co-localized and functionally interact in the hippocampus: a possible key mechanism in the modulation of N-methyl-d-aspartate effects. J Neurochem 95:1188–1200. /10.1111/j.1471-4159.2005.03455.x [DOI] [PubMed]
- 39.Temido-Ferreira M, Ferreira DG, Batalha VL, et al (2018) Age-related shift in LTD is dependent on neuronal adenosine A2A receptors interplay with mGluR5 and NMDA receptors. Mol psychiatry 1–25. /10.1038/s41380-018-0110-9 [DOI] [PMC free article] [PubMed]
- 40.Krania P, Dimou E, Bantouna M, et al (2018) Adenosine a 2A receptors are required for glutamate mGluR5- and dopamine D1 receptor-evoked ERK1/2 phosphorylation in rat hippocampus: involvement of NMDA receptor. J Neurochem 145:217–231. /10.1111/jnc.14268 [DOI] [PubMed]
- 41.Sebastiao AM, de Mendonca A, Moreira T, Ribeiro JA (2001) Activation of synaptic NMDA receptors by action potential-dependent release of transmitter during hypoxia impairs recovery of synaptic transmission on reoxygenation. J Neurosci 21:8564–8571 [DOI] [PMC free article] [PubMed]
- 42.Zhang DS, Ren LM, Zhang L (2004) [Relation between adenosine A1 receptor and NMDA receptor on synaptic transmission in dentate gyrus of hippocampus]. Yao Xue Xue Bao 39:245–249 [PubMed]
- 43.Costenla AR, Diogenes MJ, Canas PM, et al. Enhanced role of adenosine a(2A) receptors in the modulation of LTP in the rat hippocampus upon ageing. Eur J Neurosci. 2011;34:12–21. doi: 10.1111/j.1460-9568.2011.07719.x. [DOI] [PubMed] [Google Scholar]
- 44.Cunha RA. How does adenosine control neuronal dysfunction and neurodegeneration? J Neurochem. 2016;139:1019–1055. doi: 10.1111/jnc.13724. [DOI] [PubMed] [Google Scholar]
- 45.Ribeiro FF, Xapelli S, Miranda-Lourenco C, et al. Purine nucleosides in neuroregeneration and neuroprotection. Neuropharmacology. 2016;104:226–242. doi: 10.1016/j.neuropharm.2015.11.006. [DOI] [PubMed] [Google Scholar]
- 46.Dong ZS, Cao ZP, Shang YJ, et al. Neuroprotection of cordycepin in NMDA-induced excitotoxicity by modulating adenosine A1 receptors. Eur J Pharmacol. 2019;853:325–335. doi: 10.1016/j.ejphar.2019.04.015. [DOI] [PubMed] [Google Scholar]
- 47.Jeronimo-Santos A, Vaz SH, Parreira S, et al. Dysregulation of TrkB receptors and BDNF function by amyloid-beta peptide is mediated by Calpain. Cereb cortex. 2015;25:3107–3121. doi: 10.1093/cercor/bhu105. [DOI] [PubMed] [Google Scholar]
- 48.Ferreira DG, Temido-Ferreira M, Miranda H V, et al (2017) Alpha-synuclein interacts with PrP(C) to induce cognitive impairment through mGluR5 and NMDAR2B. Nat Neurosci 20:1569–1579. /10.1038/nn.4648 [DOI] [PubMed]
- 49.Horvat A, Zorec R, Vardjan N. Adrenergic stimulation of single rat astrocytes results in distinct temporal changes in intracellular Ca(2+) and cAMP-dependent PKA responses. Cell calcium. 2016;59:156–163. doi: 10.1016/j.ceca.2016.01.002. [DOI] [PubMed] [Google Scholar]
- 50.Dunwiddie TV, Masino SA. The role and regulation of adenosine in the central nervous system. Annu rev Neurosci. 2001;24:31–55. doi: 10.1146/annurev.neuro.24.1.31. [DOI] [PubMed] [Google Scholar]
- 51.Corradetti R, Lo Conte G, Moroni F, et al. Adenosine decreases aspartate and glutamate release from rat hippocampal slices. Eur J Pharmacol. 1984;104:19–26. doi: 10.1016/0014-2999(84)90364-9. [DOI] [PubMed] [Google Scholar]
- 52.Creager R, Dunwiddie T, Lynch G. Paired-pulse and frequency facilitation in the CA1 region of the in vitro rat hippocampus. J Physiol. 1980;299:409–424. doi: 10.1113/jphysiol.1980.sp013133. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53.Zucker RS, Regehr WG. Short-term synaptic plasticity. Annu rev Physiol. 2002;64:355–405. doi: 10.1146/annurev.physiol.64.092501.114547. [DOI] [PubMed] [Google Scholar]
- 54.Ongini E, Dionisotti S, Gessi S, et al. Comparison of CGS 15943, ZM 241385 and SCH 58261 as antagonists at human adenosine receptors. Naunyn Schmiedebergs arch Pharmacol. 1999;359:7–10. doi: 10.1007/pl00005326. [DOI] [PubMed] [Google Scholar]
- 55.Ongini E, Monopoli A, Cacciari B, Baraldi PG. Selective adenosine A2A receptor antagonists. Farmaco. 2001;56:87–90. doi: 10.1016/s0014-827x(01)01024-2. [DOI] [PubMed] [Google Scholar]
- 56.Zocchi C, Ongini E, Conti A, Monopoli A, Negretti A, Baraldi PG, Dionisotti S. The non-xanthine heterocyclic compound SCH 58261 is a new potent and selective A2a adenosine receptor antagonist. J Pharmacol Exp Ther. 1996;276:398–404. [PubMed] [Google Scholar]
- 57.Iacobucci GJ, Popescu GK. NMDA receptors: linking physiological output to biophysical operation. Nat rev Neurosci. 2017;18:236–249. doi: 10.1038/nrn.2017.24. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58.Sebastião AM, Ribeiro JA. Neuromodulation and metamodulation by adenosine: impact and subtleties upon synaptic plasticity regulation. Brain res. 2015;1621:102–113. doi: 10.1016/j.brainres.2014.11.008. [DOI] [PubMed] [Google Scholar]
- 59.Daly JW, Fredholm BB. Caffeine--an atypical drug of dependence. Drug Alcohol Depend. 1998;51:199–206. doi: 10.1016/S0376-8716(98)00077-5. [DOI] [PubMed] [Google Scholar]
- 60.Simons SB, Caruana DA, Zhao M, Dudek SM. Caffeine-induced synaptic potentiation in hippocampal CA2 neurons. Nat Neurosci. 2012;15:23–25. doi: 10.1038/nn.2962. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61.Martín ED, Buño W. Caffeine-mediated presynaptic long-term potentiation in hippocampal CA1 pyramidal neurons. J Neurophysiol. 2003;89:3029–3038. doi: 10.1152/jn.00601.2002. [DOI] [PubMed] [Google Scholar]
- 62.McKinney RA. Excitatory amino acid involvement in dendritic spine formation, maintenance and remodelling. J Physiol. 2010;588:107–116. doi: 10.1113/jphysiol.2009.178905. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63.Manent JB, Represa A. Neurotransmitters and brain maturation: early paracrine actions of GABA and glutamate modulate neuronal migration. Neuroscientist. 2007;13:268–279. doi: 10.1177/1073858406298918. [DOI] [PubMed] [Google Scholar]
- 64.Schlett K. Glutamate as a modulator of embryonic and adult neurogenesis. Curr Top Med Chem. 2006;6:949–960. doi: 10.2174/156802606777323665. [DOI] [PubMed] [Google Scholar]
- 65.Traynelis SF, Wollmuth LP, McBain CJ, et al. Glutamate receptor ion channels: structure, regulation, and function. Pharmacol rev. 2010;62:405–496. doi: 10.1124/pr.109.002451. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 66.Allene C, Cossart R. Early NMDA receptor-driven waves of activity in the developing neocortex: physiological or pathological network oscillations? J Physiol. 2010;588:83–91. doi: 10.1113/jphysiol.2009.178798. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 67.Pereira-Figueiredo D, Brito R, Araújo DSM, et al (2020) Caffeine exposure ameliorates acute ischemic cell death in avian developing retina. Purinergic signal 16:41–59. /10.1007/s11302-020-09687-1 [DOI] [PMC free article] [PubMed]
- 68.Silva CG, Métin C, Fazeli W, et al (2013) Adenosine receptor antagonists including caffeine alter fetal brain development in mice. Sci Transl med 5:197ra104-197ra104. /10.1126/scitranslmed.3006258 [DOI] [PubMed]
- 69.Diógenes MJ, Assaife-Lopes N, Pinto-Duarte A, et al. Influence of age on BDNF modulation of hippocampal synaptic transmission: interplay with adenosine A2A receptors. Hippocampus. 2007;17:577–585. doi: 10.1002/hipo.20294. [DOI] [PubMed] [Google Scholar]
- 70.Dumas TC, Foster TC. Late developmental changes in the ability of adenosine A1 receptors to regulate synaptic transmission in the hippocampus. Brain Res Dev Brain Res. 1998;105:137–139. doi: 10.1016/S0165-3806(97)00152-1. [DOI] [PubMed] [Google Scholar]
- 71.Coppi E, Pugliese AM, Stephan H, et al. Role of P2 purinergic receptors in synaptic transmission under normoxic and ischaemic conditions in the CA1 region of rat hippocampal slices. Purinergic signal. 2007;3:203–219. doi: 10.1007/s11302-006-9049-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 72.Fusco I, Cherchi F, Catarzi D, et al. Functional characterization of a novel adenosine A2B receptor agonist on short-term plasticity and synaptic inhibition during oxygen and glucose deprivation in the rat CA1 hippocampus. Brain res bull. 2019;151:174–180. doi: 10.1016/j.brainresbull.2019.05.018. [DOI] [PubMed] [Google Scholar]
- 73.Markram H, Segal M. The inositol 1,4,5-trisphosphate pathway mediates cholinergic potentiation of rat hippocampal neuronal responses to NMDA. J Physiol. 1992;447:513–533. doi: 10.1113/jphysiol.1992.sp019015. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 74.Clark KA, Randall AD, Collingridge GL. A comparison of paired-pulsed facilitation of AMPA and NMDA receptor-mediated excitatory postsynaptic currents in the hippocampus. Exp brain res. 1994;101:272–278. doi: 10.1007/bf00228747. [DOI] [PubMed] [Google Scholar]
- 75.Fontinha BM, Delgado-García JM, Madroñal N, et al. Adenosine a(2A) receptor modulation of hippocampal CA3-CA1 synapse plasticity during associative learning in behaving mice. Neuropsychopharmacology. 2009;34:1865–1874. doi: 10.1038/npp.2009.8. [DOI] [PubMed] [Google Scholar]
- 76.Pedata F, Pepeu G, Spignoli G. Biphasic effect of methylxanthines on acetylcholine release from electrically-stimulated brain slices. Br J Pharmacol. 1984;83:69–73. doi: 10.1111/j.1476-5381.1984.tb10120.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 77.Spignoli G, Pedata F, Pepeu G. A1 and A2 adenosine receptors modulate acetylcholine release from brain slices. Eur J Pharmacol. 1984;97:341–342. doi: 10.1016/0014-2999(84)90475-8. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
Not applicable